StockData
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC (ADAPY) stock

ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025Score 3/30
$0.04+0.00 (+9.38%)

Close on Oct 19, 2026Market cap $55.46MP/E –Yield –

Adaptimmune Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2024 it was $177.96M.

Annual gross profit

PeriodPeriod endValueChange
FY2024Dec 31, 2024$177.96M–

Quarterly gross profit

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2025CQ2 2025Jun 30, 2025$11.18M–
Q1 FY2025CQ1 2025Mar 31, 2025$6.41M–

More Adaptimmune Therapeutics figures

See a number that looks wrong?